

Parkinson's Disease Research Studies Currently Enrolling

Fall 2010



Parkinson's Disease A study to evaluate the efficacy and safety of pralidoxime in subject with early Parkinson's

- ≥ 30 to ≤ 85 years of age
- Diagnosis of idiopathic PD
- Can't be on L-dopa or dopamine agonist

Parkinson's Disease A study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic PD, treated with dopamine agonist

- 30-80 years old
- Diagnosis of idiopathic PD less than 5 years
- On stable dose of dopamine agonist 4 weeks prior

Parkinson's Disease A study to evaluate the efficacy and safety of pralidoxime in subjects with moderate to severe Parkinson's

- ≥ 30 to ≤ 85 years of age
- Diagnosis of idiopathic PD
- Must be on a stable dose of L-dopa for approximately 2 or more years

Parkinson's Disease A study to determine the efficacy and safety of a dose range of 50 to 100mg/daily of safinamide, as add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluctuations treated with a stable dose of levodopa (Sinemet)

- 30-80 years old
- Diagnosis of idiopathic PD of more than 5 years
- On stable dose of levodopa 4 weeks prior

Questions can be submitted to the Research Department by email: research@neuro-institute.com

Research Department Contacts: Myrna Shrum 704-335-6483 • Marguerite Buckley 704-331-7856
2607 East 7th Street, Suite 200, Charlotte, NC 28204 • www.neuro-institute.com